Deep Science Ventures and General Inception collaborate to create fibrosis-focused therapeutics company
· News-MedicalDeep Science Ventures, a UK-based venture studio, and General Inception, a US-based venture studio, today announced a collaboration to create a company focused on developing novel treatments for fibrosis. Widely recognized as an area of significant unmet need, Deep Science Ventures and General Inception’s European arm, Igniter Europe, aim to establish a company dedicated to overcoming current bottlenecks in fibrosis therapeutics by developing a novel concept and taking it through to full company launch.
Deep Science Ventures has built and launched over 40 companies harnessing scientific invention to solve major world challenges, combining interdisciplinary expertise to develop solutions in fields such as therapeutics, climate, restorative agriculture and computation. Deep Science Ventures’ methodology focuses on iteratively profiling the techno-economic requirements and generating matched candidate solutions. The methodology is accelerated by a proprietary ’AI co-pilot’ tool which automates critical invention workflows.
General Inception provides strategic support, capital, and resources through its venture studio, which has built a portfolio of 45 companies across therapeutics, synthetic biology and life science tools and diagnostics. Igniter Europe, General Inception’s European arm, focuses on the growth of high-potential European ventures, particularly in therapeutics and life sciences tools and technology sectors. Igniter Europe will provide scientific and operational expertise to support the build process of the new company.
Dr Laura Fletcher, Head of Business Development and Venture Portfolio, Pharma, Deep Science VenturesWe are pleased to partner with General Inception to address the critical unmet need in fibrosis and the need for more impactful treatments. Our approach, driven by medical need rather than technology-led solutions, leverages the complementary strengths of our two venture studios. Together, we will develop an approach to tackle fibrosis, and we are excited to see the impact this will have on patients.”
Source: